Navigation Links
MicuRx Completes $25 Million Series B Financing
Date:8/22/2013

HAYWARD, Calif. and SHANGHAI, Aug. 22, 2013 /PRNewswire/ -- MicuRx Pharmaceuticals, Inc., a privately-held biopharmaceutical company developing next-generation antibiotics, today announced it raised $25 million in Series B financing. Led by BVCF, a private equity and growth fund specializing in the life sciences industry, the round also includes existing investors Morningside Group and Devon Park Bioventures.

Proceeds from the Series B financing will be used to fund the U.S. development of MRX-I, a novel oral oxazolidinone antibiotic targeting infections due to multi-drug resistant Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE). Weixin Xu and Davis Yang of BVCF will join the MicuRx board of directors.

"We invest in companies with experienced management teams and sound strategic plans," said Zhi Yang, general partner at BVCF. "We look forward to supporting the parallel development of MRX-I in the United States and China, as this novel antibiotic has the potential to offer an attractive option for addressing the growing threat of multi-drug resistant bacteria."

"MicuRx's unusually high capital efficiency in their first six years of operation is exceptional for antibiotic development," commented Zhengyu Yuan, Ph.D., president and chief executive officer of MicuRx Pharmaceuticals, Inc. "Using a US-China hybrid discovery and development model, MicuRx successfully completed design and optimization of its novel oxazolidinone drug candidates and advanced MRX-I through Phase-1 clinical trials with a fraction of the capital required through a traditional operating model in the United States. With the initiation of Phase 2 clin
'/>"/>

SOURCE MicuRx Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. MicuRx Pharmaceuticals Announces Issuance Of U.S. Patent For Its Next-Generation Antibacterial Agent
2. HeartWare Completes Enrollment In 450-Patient Pivotal Destination Therapy Clinical Trial
3. Novelos Therapeutics Successfully Completes First Cohort In Phase 1b Solid Tumor Trial With I-131-CLR1404 (HOT) Cancer-Targeted Molecular Radiotherapeutic
4. NuMe Health Completes $1.5 Million Series A Financing To Advance Its First Cobioticâ„¢ Aimed At Helping Prediabetics Maintain Healthy Blood Glucose Levels
5. CryoLife Completes Acquisition of Hemosphere
6. Bausch + Lomb Completes the Acquisition of ISTA Pharmaceuticals
7. Savara Pharmaceuticals Completes Phase I Clinical Study of AeroVanc in Cystic Fibrosis Patients
8. Jazz Pharmaceuticals Completes EUSA Pharma Acquisition
9. Amgen Completes Acquisition of Mustafa Nevzat Pharmaceuticals
10. Ablative Solutions Completes $5.3M Series A Financing
11. Quantum OPS Completes $1.05M In Series A Financing To Advance Surgical Devices
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... THOUSAND OAKS, Calif. , Jan. 15, 2014 ... and Amgen (NASDAQ: AMGN ) announced ... to jointly discover and validate new therapeutic targets ... (IBD), a chronic disorder that affects millions worldwide. ...
(Date:1/15/2014)... WORTH, Texas , Jan. 15, 2014  Humberto C. ... Dermatology Achievement Award" from the Journal of Drugs ... Aesthetic & Clinical Conference (ODAC). The event is January 17-20, ... Florida . The ODAC ...
(Date:1/15/2014)... Ky. , Jan. 15, 2014  Manufacturers, suppliers ... must be able to protect their most important ... http://photos.prnewswire.com/prnh/20130716/CL46586LOGO ) Because of ... it steadfastly remains one of the most litigious ...
Breaking Medicine Technology:Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4Intellectual Property Insurance for Medical-related Products and Services 2
... Watson Pharmaceuticals, Inc. (NYSE: WPI ), a ... intends to release its first quarter 2011 financial results on ... U.S. financial markets.  The Company will also host a conference ... 27, 2011 to discuss its financial results and provide an ...
... RESMED INC. (NYSE: RMD ), announced today that ... for the third quarter and nine months of fiscal year ... results will be issued after 1:00 p.m. Pacific Time and ... review its results, market trends, and future outlook. ...
Cached Medicine Technology:Watson to Host Conference Call and Webcast to Discuss First Quarter 2011 Earnings 2ResMed Announces Conference Call and Webcast to Discuss Third Quarter 2011 Results 2
(Date:4/17/2014)... Meaningful long-term survival is possible for selected patients ... treated with cytoreductive surgery with Hyperthermic IntraPeritoneal Chemotherapy, ... physicians at Wake Forest Baptist Medical Center. , ... experience with cytoreductive surgery and HIPEC, said lead ... 20 years, worth of patient data shows that ...
(Date:4/17/2014)... per cent of Canadians surveyed said they would participate ... specific number of genetic conditions, only 80 per cent ... that would sequence their newborns, genomes.,Most newborns in North ... day or two of life in which a tiny ... tested for about five to 54 conditions, depending on ...
(Date:4/17/2014)... have called for more research to be carried ... in sub-Saharan Africa. In a paper in ... Stothard, working with colleagues in the department of ... in Cleveland Ohio, University of Cambridge and the ... the joint burden of HIV/AIDS and schistosomiasis of ...
(Date:4/16/2014)... ANTONIO, Texas (April 16, 2014) A team that includes ... Texas Health Science Center at San Antonio, Johns Hopkins University ... that helps a common fungus to infect the body. , ... diaper rashes and oral thrush, and is the most common ...
(Date:4/15/2014)... nearly half of all injuries aboard commercial freezer-trawlers and ... operating off the coast of Alaska, new research from ... and others aboard the two types of vessels could ... methods used in the study could help identify and ...
Breaking Medicine News(10 mins):Health News:20 years of data shows treatment technique improvement for advanced abdominal cancer 2Health News:Researcher looks at public perceptions around newborn testing 2Health News:Researcher looks at public perceptions around newborn testing 3Health News:More research called for into HIV and schistosomiasis coinfection in African children 2Health News:Changes in processing, handling could reduce commercial fishing injuries 2
... skilled negotiators when it comes to relationships and the ... of Gothenburg, Sweden. The thesis examines what children ... use. The results show that young children are skilled ... children learn, through play, which negotiation strategies are appropriate ...
... Findings worrisome because thyroid hormones play critical role in ... News) -- Exposure to flame-retardant chemicals may reduce a ... a critical role in fetal brain development, a new ... are used in a large number of consumer products, ...
... and Dora to market treats should be banned, researcher ... cartoon characters are influencing the taste preferences of very ... new study suggests. , Researchers found that the branding ... Dora the Explorer drives preschoolers to choose higher-calorie, less ...
... ... you might hope to want or need for the sunny weather to come! , ... London, UK (PRWEB) June 19, 2010 -- The summer is pretty much ... best. Fear not, for anyone stuck in London without so much as a grain of sand in ...
... ... Horizon Healthcare Services, Inc. to Put Evidence-Based Medicine into Practice with Via Oncology Pathways ... Pittsburgh ... will continue to improve as a result of wider application of Via Oncology™ Pathways, ...
... ... form of release and expression, and now it has been fine-tuned to deliver mental rejuvenation ... ... this world, it can be difficult for the average person to relax or even get ...
Cached Medicine News:Health News:Young children are skilled negotiators 2Health News:Flame Retardant May Up Risk of Thyroid Problems in Pregnancy 2Health News:Cartoon Characters Sell Kids on Unhealthy Foods 2Health News:Cartoon Characters Sell Kids on Unhealthy Foods 3Health News:Summer is Here - The Best Value Luxury Manicures, Spa Packages and Spa Waxing from Kuno Tierra, Mayfair Spa 2Health News:Hematology-Oncology Associates of Northern New Jersey (HOANNJ) Joins Effort to Improve Cancer Care with Via Oncology™ Pathways 2Health News:Hematology-Oncology Associates of Northern New Jersey (HOANNJ) Joins Effort to Improve Cancer Care with Via Oncology™ Pathways 3Health News:Reinvent your Mental State With Brainwave Entrainment Relaxation Music 2Health News:Reinvent your Mental State With Brainwave Entrainment Relaxation Music 3Health News:Reinvent your Mental State With Brainwave Entrainment Relaxation Music 4
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: